These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 9258962

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA, Abdella MM.
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [Abstract] [Full Text] [Related]

  • 3. [The decreased level of plasma carnitine in patients with epilepsy].
    Belousova ED.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017 Sep; 117(6):106-110. PubMed ID: 28745680
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. L-carnitine supplementation in childhood epilepsy: current perspectives.
    De Vivo DC, Bohan TP, Coulter DL, Dreifuss FE, Greenwood RS, Nordli DR, Shields WD, Stafstrom CE, Tein I.
    Epilepsia; 1998 Nov; 39(11):1216-25. PubMed ID: 9821988
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Valproate therapy does not deplete carnitine levels in otherwise healthy children.
    Hirose S, Mitsudome A, Yasumoto S, Ogawa A, Muta Y, Tomoda Y.
    Pediatrics; 1998 May; 101(5):E9. PubMed ID: 9565442
    [Abstract] [Full Text] [Related]

  • 9. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
    Kondo T, Ishida M, Kaneko S, Hirano T, Otani K, Fukushima Y, Muranaka H, Koide N, Yokoyama M, Nakata S.
    Epilepsia; 1992 May; 33(3):550-4. PubMed ID: 1350534
    [Abstract] [Full Text] [Related]

  • 10. Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation.
    Schiavo A, Maldonado C, Vázquez M, Fagiolino P, Trocóniz IF, Ibarra M.
    Eur J Pharm Sci; 2023 Apr 01; 183():106399. PubMed ID: 36740101
    [Abstract] [Full Text] [Related]

  • 11. [The problems of valproate therapy in severely handicapped children--valproate induced hyperammonemia and hypocarnitinemia].
    Matsui K, Iwamoto H, Ohtsuki N, Kobayashi T, Miyake S, Yamada M.
    No To Hattatsu; 1991 Jan 01; 23(1):32-8. PubMed ID: 1825272
    [Abstract] [Full Text] [Related]

  • 12. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ, Lluch-Fernández MD, Vaquero-Abellán M, Marchante-Serrano C, Jiménez C.
    Rev Neurol; 1997 Jul 01; 25(143):1037-44. PubMed ID: 9280630
    [Abstract] [Full Text] [Related]

  • 13. [Hyperammonemia in valproate therapy in children and adolescents].
    Laub MC.
    Nervenarzt; 1986 May 01; 57(5):314-8. PubMed ID: 3088461
    [Abstract] [Full Text] [Related]

  • 14. Hyperammonemia following intravenous valproate loading.
    DeWolfe JL, Knowlton RC, Beasley MT, Cofield S, Faught E, Limdi NA.
    Epilepsy Res; 2009 Jul 01; 85(1):65-71. PubMed ID: 19299111
    [Abstract] [Full Text] [Related]

  • 15. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs.
    Thom H, Carter PE, Cole GF, Stevenson KL.
    Dev Med Child Neurol; 1991 Sep 01; 33(9):795-802. PubMed ID: 1936631
    [Abstract] [Full Text] [Related]

  • 16. Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy.
    Tseng YL, Huang CR, Lin CH, Lu YT, Lu CH, Chen NC, Chang CC, Chang WN, Chuang YC.
    Medicine (Baltimore); 2014 Sep 01; 93(11):e66. PubMed ID: 25192484
    [Abstract] [Full Text] [Related]

  • 17. Alterations in the carnitine metabolism in epileptic children treated with valproic acid.
    Chung S, Choi J, Hyun T, Rha Y, Bae C.
    J Korean Med Sci; 1997 Dec 01; 12(6):553-8. PubMed ID: 9443096
    [Abstract] [Full Text] [Related]

  • 18. [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
    Yamada H, Shishido T, Mukai T, Araki M, Naka H, Tokinobu H.
    Rinsho Shinkeigaku; 2019 May 28; 59(5):258-263. PubMed ID: 31061301
    [Abstract] [Full Text] [Related]

  • 19. Effect of associated antiepileptic treatment on valproate-induced hyperammonemia.
    Zaccara G, Paganini M, Campostrini R, Moroni F, Valenza T, Messori A, Bartelli M, Arnetoli G, Zappoli R.
    Ther Drug Monit; 1985 May 28; 7(2):185-90. PubMed ID: 3927530
    [Abstract] [Full Text] [Related]

  • 20. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
    Goto S, Seo T, Hagiwara T, Ueda K, Yamauchi T, Nagata S, Ando Y, Ishitsu T, Nakagawa K.
    J Pharm Pharmacol; 2008 Feb 28; 60(2):267-72. PubMed ID: 18237476
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.